Learn more about whether Alkermes plc or Zymeworks Inc. is a better investment based on AAII's A+ Investor grades, which ...

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Further to the announcement under Rule 2.7 of the Irish Takeover Rules by Avadel and Alkermes on November 19, 2025, Danish ...

In a statement, Denmark-based Lundbeck said it had carried out a "comprehensive assessment" of the bids on the table for ...

This latest corporate clash has Alkermes working to beat back a challenge from H. Lundbeck for sleep disorder drug developer Avadel Pharmaceuticals.

The consensus analyst price target for Alkermes stock was recently lowered from $44 to $43.88, following several updates to the company’s outlook. This minor adjustment reflects a combination of ...

Johnson & Johnson entered into a definitive agreement to acquire Halda Therapeutics OpCo for $3.05 billion in cash. Eli Lilly announced it will pay $40 million upfront and up to $2.56 billion in a ...

Shares of Agios Pharmaceuticals AGIO tanked about 51% on Wednesday after it reported mixed top-line results from the phase ...

Ireland-based Alkermes (Nasdaq: ALKS) has upped its offer to buy Avadel Pharmaceuticals (Nasdaq: AVDL). Under the improved ...

Lundbeck had tried to scoop the narcolepsy drug maker out from under Alkeremes with $2.4 billion, but Avadel has elected to ...

Alkermes ups bid for Avadel as Lundbeck looms; Severe flu season could be on the way for U.S.; Can GLP-1s treat Alzheimer’s?

Alkermes ( (ALKS) ) has shared an announcement. On November 18, 2025, Alkermes plc and Avadel Pharmaceuticals plc amended their transaction agreement, increasing the cash consideration for the ...